Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
43 hedge funds and large institutions have $88M invested in Esperion Therapeutics in 2014 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
70% more capital invested
Capital invested by funds: $51.9M → $88M (+$36.1M)
8% more funds holding
Funds holding: 40 → 43 (+3)
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aisling Capital
New York
|
+$29.7M |
| 2 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$1.64M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.59M |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
+$348K |
| 5 |
SIM
SSI Investment Management
Los Angeles,
California
|
+$258K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
-$1.13M |
| 2 |
FWIA
Fort Washington Investment Advisors
Cincinnati,
Ohio
|
-$886K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$256K |
| 4 |
Morgan Stanley
New York
|
-$146K |
| 5 |
IHM
Iguana Healthcare Management
New York
|
-$144K |
ESPR Hedge Fund Activity: Q2 2014 in Review
43 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q2 2014, worth a combined $88M — up 70% from $51.9M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ESPR positions and 3 closed out — a net gain of 3 holders — while 17 added to existing stakes and 16 trimmed.
The largest buyer was Aisling Capital, opening a new position worth an estimated $29.7M. The largest seller was Polar Capital, cutting an estimated $1.13M.
- 43 institutional investors held Esperion Therapeutics (ESPR) as of Q2 2014, up from 40 in Q1 2014.
- Funds reported $88M of Esperion Therapeutics stock for Q2 2014, up 70% quarter-over-quarter.
- 6 funds opened new Esperion Therapeutics positions in Q2 2014 and 3 closed out, a net change of +3 holders.
- The largest Esperion Therapeutics buyer in Q2 2014 was Aisling Capital, an estimated $29.7M added.
- The largest Esperion Therapeutics seller in Q2 2014 was Polar Capital, an estimated $1.13M sold.
Based on aggregated 13F filings for Q2 2014.